# US 2012/0252793 A1 · Intranasal benzodiazepine pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252793 A1
- Document ID: US20120252793A1
- Status: Published application
- Kind: A1
- Application number: 13/435,837
- Filed: 2012-03-30
- Published: 2012-10-04
- Earliest claimed: 2011-03-31
- Inventors: Gary Bream; Moise A. Khayrallah; Myoung-Ki Baek; Jae-Hoon Jo; Hye-Jin Chang
- Web page: https://patentgrep.com/patent/US20120252793A1

## CPC

- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 9/0043: {Nose}
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/22: Anxiolytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention generally relates to intranasal pharmaceutical compositions comprising a benzodiazepine and methods of use thereof that can provide a therapeutic effect without a decrease in blood pressure and/or pulse after administration of the pharmaceutical composition.

## Claims

### Claim 1

A pharmaceutical composition comprising about 1% to about 15% by weight of a benzodiazepine or a pharmaceutically acceptable salt thereof, about 43% to about 55% by weight of a glycol ether, about 16% to about 18% by weight one or more fatty acid esters, about 22% to about 25% by weight N-methyl-2-pyrrolidone, about 1% to about 5% by weight water, and about 5% to about 10% by weight ethanol.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, comprising about 1% to about 15% by weight diazepam or a pharmaceutically acceptable salt thereof, about 43% to about 55% by weight diethylene glycol monoethyl ether, about 9% to about 10% by weight methyl laurate, about 7% to about 9% by weight propylene glycol monocaprylate, about 22% to about 25% by weight N-methyl-2-pyrrolidone, about 1% to about 5% by weight water, and about 5% to about 10% by weight ethanol.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, comprising 2.50% by weight diazepam or a pharmaceutically acceptable salt thereof, 48.20% by weight diethylene glycol monoethyl ether, 7.60% by weight propylene glycol monocaprylate, 9.50% by weight methyl laurate, 22.70% by weight N-methyl-2-pyrrolidone, 7.60% by weight ethanol, and 1.90% by weight water.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, comprising 3.75% by weight diazepam or a pharmaceutically acceptable salt thereof, 46.95% by weight diethylene glycol monoethyl ether, 7.60% by weight propylene glycol monocaprylate, 9.50% by weight methyl laurate, 22.70% by weight N-methyl-2-pyrrolidone, 7.60% by weight ethanol, and 1.90% by weight water.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, comprising 5.00% by weight diazepam or a pharmaceutically acceptable salt thereof, 45.70% by weight diethylene glycol monoethyl ether, 7.60% by weight propylene glycol monocaprylate, 9.50% by weight methyl laurate, 22.70% by weight N-methyl-2-pyrrolidone, 7.60% by weight ethanol, and 1.90% by weight water.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, comprising 6.25% by weight diazepam or a pharmaceutically acceptable salt thereof, 44.45% by weight diethylene glycol monoethyl ether, 7.60% by weight propylene glycol monocaprylate, 9.50% by weight methyl laurate, 22.70% by weight N-methyl-2-pyrrolidone, 7.60% by weight ethanol, and 1.90% by weight water.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, comprising 7.50% by weight diazepam or a pharmaceutically acceptable salt thereof, 43.20% by weight diethylene glycol monoethyl ether, 7.60% by weight propylene glycol monocaprylate, 9.50% by weight methyl laurate, 22.70% by weight N-methyl-2-pyrrolidone, 7.60% by weight ethanol, and 1.90% by weight water.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, comprising 8.75% by weight diazepam or a pharmaceutically acceptable salt thereof, 41.95% by weight diethylene glycol monoethyl ether, 7.60% by weight propylene glycol monocaprylate, 9.50% by weight methyl laurate, 22.70% by weight N-methyl-2-pyrrolidone, 7.60% by weight ethanol, and 1.90% by weight water.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, comprising 10.00% by weight diazepam or a pharmaceutically acceptable salt thereof, 40.70% by weight diethylene glycol monoethyl ether, 7.60% by weight propylene glycol monocaprylate, 9.50% by weight methyl laurate, 22.70% by weight N-methyl-2-pyrrolidone, 7.60% by weight ethanol, and 1.90% by weight water.

### Claim 10

A pharmaceutical composition comprising about 1% to about 10% by weight of a benzodiazepine or a pharmaceutically acceptable salt thereof, about 40% to about 47% by weight of a glycol ether, and about 45% to about 55% by weight one or more fatty acid esters.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, further comprising about 0.5% to about 3% by weight water.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, comprising about 1% to about 10% by weight diazepam or a pharmaceutically acceptable salt thereof, about 40% to about 47% by weight diethylene glycol monoethyl ether, about 26% to about 34% by weight caprylocaproyl polyoxylglyceride, about 5% to about 10% by weight oleoyl polyoxylglyceride, and about 5% to about 15% by weight sorbitan monolaurate 20.

### Claim 13 (depends on 10)

The pharmaceutical composition of claim 10, comprising 4.95% by weight diazepam or a pharmaceutically acceptable salt thereof, 45.62% by weight diethylene glycol monoethyl ether, 30.42% by weight caprylocaproyl polyoxylglyceride, 7.6% by weight oleoyl polyoxylglyceride, and 11.41% by weight sorbitan monolaurate 20.

### Claim 14 (depends on 10)

The pharmaceutical composition of claim 10, comprising 6.63% by weight diazepam or a pharmaceutically acceptable salt thereof, 44.82% by weight diethylene glycol monoethyl ether, 29.88% by weight caprylocaproyl polyoxylglyceride, 7.47% by weight oleoyl polyoxylglyceride, and 11.20% by weight sorbitan monolaurate 20.

### Claim 15 (depends on 11)

The pharmaceutical composition of claim 11, comprising about 1% to about 10% by weight diazepam or a pharmaceutically acceptable salt thereof, about 40% to about 47% by weight diethylene glycol monoethyl ether, about 26% to about 34% by weight caprylocaproyl polyoxylglyceride, about 5% to about 10% by weight isopropyl palmitate, about 5% to about 15% by weight sorbitan monolaurate 20, and about 0.5% to about 3% by weight water.

### Claim 16 (depends on 11)

The pharmaceutical composition of claim 11, comprising 2.50% by weight diazepam or a pharmaceutically acceptable salt thereof, 48.10% by weight diethylene glycol monoethyl ether, 7.30% by weight isopropyl palmitate, 10.80% by weight sorbitan monolaurate 20, 30.30% by weight caprylocaproyl polyoxylglyceride, and 1.00% by weight water.

### Claim 17 (depends on 11)

The pharmaceutical composition of claim 11, comprising 3.75% by weight diazepam or a pharmaceutically acceptable salt thereof, 46.85% by weight diethylene glycol monoethyl ether, 7.30% by weight isopropyl palmitate, 10.80% by weight sorbitan monolaurate 20, 30.30% by weight caprylocaproyl polyoxylglyceride, and 1.00% by weight water.

### Claim 18 (depends on 11)

The pharmaceutical composition of claim 11, comprising 5.0% by weight diazepam or a pharmaceutically acceptable salt thereof, 45.60% by weight diethylene glycol monoethyl ether, 7.30% by weight isopropyl palmitate, 10.80% by weight sorbitan monolaurate 20, 30.30% by weight caprylocaproyl polyoxylglyceride, and 1.00% by weight water.

### Claim 19 (depends on 11)

The pharmaceutical composition of claim 11, comprising 5.0% by weight diazepam or a pharmaceutically acceptable salt thereof, 45.60% by weight diethylene glycol monoethyl ether, 7.22% by weight isopropyl palmitate, 10.83% by weight sorbitan monolaurate 20, 30.40% by weight caprylocaproyl polyoxylglyceride, and 0.95% by weight water.

### Claim 20 (depends on 11)

The pharmaceutical composition of claim 11, comprising 6.25% by weight diazepam or a pharmaceutically acceptable salt thereof, 44.35% by weight diethylene glycol monoethyl ether, 7.30% by weight isopropyl palmitate, 10.80% by weight sorbitan monolaurate 20, 30.30% by weight caprylocaproyl polyoxylglyceride, and 1.00% by weight water.

### Claim 21 (depends on 11)

The pharmaceutical composition of claim 11, comprising 7.50% by weight diazepam or a pharmaceutically acceptable salt thereof, 43.10% by weight diethylene glycol monoethyl ether, 7.30% by weight isopropyl palmitate, 10.80% by weight sorbitan monolaurate 20, 30.30% by weight caprylocaproyl polyoxylglyceride, and 1.00% by weight water.

### Claim 22 (depends on 11)

The pharmaceutical composition of claim 11, comprising 8.75% by weight diazepam or a pharmaceutically acceptable salt thereof, 41.85% by weight diethylene glycol monoethyl ether, 7.30% by weight isopropyl palmitate, 10.80% by weight sorbitan monolaurate 20, 30.30% by weight caprylocaproyl polyoxylglyceride, and 1.00% by weight water.

### Claim 23 (depends on 11)

The pharmaceutical composition of claim 11, comprising 10.00% by weight diazepam or a pharmaceutically acceptable salt thereof, 40.60% by weight diethylene glycol monoethyl ether, 7.30% by weight isopropyl palmitate, 10.80% by weight sorbitan monolaurate 20, 30.30% by weight caprylocaproyl polyoxylglyceride, and 1.00% by weight water.

### Claim 24 (depends on 1)

The pharmaceutical composition of claim 1, wherein the benzodiazepine is diazepam.

### Claim 25 (depends on 1)

The pharmaceutical composition of claim 1, wherein the glycol ether is diethylene glycol monoethyl ether.

### Claim 26 (depends on 1)

The pharmaceutical composition of claim 1, wherein the one or more fatty acid esters is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, polysorbate 20, propylene glycol monocaprylate, and any combination thereof.

### Claim 27 (depends on 1)

The pharmaceutical composition of claim 1, wherein the one or more fatty acid esters is selected from the group consisting of methyl laurate, propylene glycol monocaprylate, and any combination thereof.

### Claim 28 (depends on 10)

The pharmaceutical composition of claim 10, wherein the one or more fatty acid esters is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, sorbitan monolaurate 20, and any combination thereof.

### Claim 29 (depends on 10)

The pharmaceutical composition of claim 10, wherein the one or more fatty acid esters is selected from the group consisting of caprylocaproyl polyoxylglyceride, oleoyl polyoxylglyceride, sorbitan monolaurate 20, and any combination thereof.

### Claim 30 (depends on 1)

The pharmaceutical composition of claim 1, in a form for intranasal administration.

### Claim 31

A pharmaceutical composition for intranasal administration of diazepam, comprising diazepam or a pharmaceutically acceptable salt thereof, a glycol ether, and one or more fatty acid esters, wherein upon administration to a human subject, plasma levels of diazepam exhibit a coefficient of variation (CV) of less than about 40%.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, wherein the CV is less than about 30%.

### Claim 33 (depends on 1)

An intranasal spray device comprising the pharmaceutical composition of claim 1.

### Claim 34 (depends on 1)

A method of treating a seizure in a subject, comprising intranasally administering a therapeutically effective amount of the pharmaceutical composition of claim 1 to a subject in need thereof.

### Claim 35 (depends on 34)

The method of claim 34, wherein after administration of the composition to a subject, the subject's blood pressure is maintained at a consistent level for at least 1 hour.

### Claim 36 (depends on 35)

The method of claim 35, wherein the subject's blood pressure after administration of the composition remains within 10/10 mmHg (SBP/DBP) of the subject's blood pressure prior to administration of the composition.

### Claim 37 (depends on 34)

The method of claim 34, wherein after administration of the composition to a subject, the subject's pulse is maintained at a consistent level for at least one hour.

### Claim 38 (depends on 37)

The method of claim 37, wherein the subject's pulse remains within 5 beats per minute of the subject's pulse prior to administration of the composition.

### Claim 39 (depends on 1)

A method of preventing a drop in blood pressure in a subject during administration of diazepam for treatment of a seizure, comprising intranasally administering a therapeutically effective amount of the pharmaceutical composition of claim 1 to a subject in need thereof.
